NovoCure Limited - Ordinary Shares (NVCR) Company Bio
NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.
NVCR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for NVCR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that NovoCure Ltd ranked in the 95th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 4108.5% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of NovoCure Ltd, consider:
The compound growth rate in the free cash flow of NovoCure Ltd over the past 1.5 years is 3.93%; that's better than 95.1% of cash flow producing equities in the Healthcare sector, where it is classified.
The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 2.24% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
NovoCure Ltd's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of NovoCure Ltd? See MNKKQ, CYH, AMEH, RDY, and BEAT.
NovoCure Ltd. is pulling back Monday and the weakness may not be over. In early November we reviewed the charts of NVCR and wrote that, "If you are still long NVCR from early October then I would continue to hold those positions but raise stop protection to a close below $110 now." In the updated daily Japanese candlestick chart of NVCR, below, we can see some upper shadows last month telling us that traders were rejecting the highs.
NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 207,910 shares of NovoCure stock in a transaction dated Friday, December 18th. The shares were sold at an average price of $157.39, for a total value of $32,722,954.90. Following the transaction, the chief executive officer now directly owns 301,587 shares in the company, valued at approximately $47,466,777.93. The […]